Eric Sullivan

Chief Financial Officer

Professional Overview

Eric Sullivan is a seasoned finance executive with over 15 years of experience in the biopharmaceutical industry. As the Chief Financial Officer at Convergent Therapeutics, Inc., he is responsible for overseeing the company's financial strategy, reporting, and operations. With a strong background in financial management, Eric has played a key role in supporting the growth and success of several leading biotechnology organizations.

Experience Summary

Current Role

As the Chief Financial Officer at Convergent Therapeutics, Inc., Eric is responsible for managing the company's financial affairs, including budgeting, forecasting, and capital raising. He works closely with the executive team to align financial strategy with the organization's overall business objectives. Under Eric's financial leadership, Convergent Therapeutics has secured significant funding to accelerate its pipeline of innovative therapeutic solutions.

Eric also serves on the Board of Directors at Chimeric Therapeutics, where he chairs the Audit & Risk Committee and is a member of the Remuneration & Nomination Committee. In this capacity, he provides strategic guidance and oversight to ensure the company's financial and operational integrity.

Career Progression

Prior to his current roles, Eric held the position of Chief Financial Officer at TCR² Therapeutics Inc., where he played a pivotal role in the company's successful acquisition by Adaptimmune. He has also served as the Chief Financial Officer and Chief Operating Officer at Triplet Therapeutics, and as the Senior Vice President of Finance at Gemini Therapeutics.

Throughout his career, Eric has demonstrated a strong track record of driving financial and operational excellence, securing strategic partnerships, and guiding companies through significant growth and transformational events.

Academic Background

Eric holds a Bachelor of Science in Accounting from the University of Massachusetts Amherst and is a Certified Public Accountant (CPA).

Areas of Expertise

• Financial strategy and management

• Mergers and acquisitions

• Fundraising and capital markets

• Operational efficiency and optimization

• Leadership and team development

Professional Impact

Under Eric's financial stewardship, the companies he has served have achieved significant milestones, including:

• Securing over $150 million in funding to support Convergent Therapeutics' pipeline development

• Guiding TCR² Therapeutics through a successful acquisition, resulting in a favorable outcome for shareholders

• Optimizing Triplet Therapeutics' financial and operational processes, leading to improved profitability and growth

Conclusion

With his extensive experience in the biopharmaceutical industry, Eric Sullivan has established himself as a strategic and results-driven finance executive. As the Chief Financial Officer at Convergent Therapeutics, he continues to play a pivotal role in the company's success, leveraging his financial expertise and industry knowledge to drive sustainable growth and value creation.